TCGA-CF-A47S-01A-11R-A23W-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.93955322
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.260
- KRAS_SIGNALING_DN+0.230
- BILE_ACID_METABOLISM+0.200
- XENOBIOTIC_METABOLISM+0.200
- TNFA_SIGNALING_VIA_NFKB+0.190
- COAGULATION+0.170
- P53_PATHWAY+0.170
- IL6_JAK_STAT3_SIGNALING+0.150
- PANCREAS_BETA_CELLS+0.130
- INTERFERON_GAMMA_RESPONSE+0.120
Top 10 suppressed
- E2F_TARGETS-0.710
- G2M_CHECKPOINT-0.680
- MITOTIC_SPINDLE-0.550
- MYC_TARGETS_V1-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.520
- MTORC1_SIGNALING-0.470
- MYC_TARGETS_V2-0.470
- PROTEIN_SECRETION-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- PI3K_AKT_MTOR_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A519-01A-11R-A26T-07 | — | — | 0.867 |
| 2 | C3L-00368 | — | cohortA1 | 0.858 |
| 3 | TCGA-91-A4BD-01A-11R-A24H-07 | — | cohortA1 | 0.856 |
| 4 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.850 |
| 5 | MNG279 | — | — | 0.846 |
| 6 | TCGA-55-8514-01A-11R-2403-07 | — | cohortA1 | 0.843 |
| 7 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.840 |
| 8 | MDT-AP-2047 | Med | Medulloblastoma | 0.835 |
| 9 | C3N-03038 | — | cohortA1 | 0.835 |
| 10 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |